Form 4: Outset CEO sells shares to cover taxes

Outset Medical CEO Leslie Trigg sold 916 shares at $4.60 in a non‑discretionary sell-to-cover tied to RSU vesting, maintaining substantial direct and trust holdings.

Summary

• On 11/17/2025, Chair and CEO (and Director) Leslie Trigg sold 916 shares of Outset Medical, Inc. (OM) common stock at $4.60 per share (transaction code S).
• The sale was solely to satisfy tax withholding obligations from the vesting of an aggregate 1,770 RSU shares granted on 01/06/2023 and 01/12/2024; it was a non-discretionary sell-to-cover transaction.
• Post-transaction direct beneficial ownership: 121,412 common shares.
• Indirect beneficial ownership: 41,666 shares via the Trigg 2002 Rev Trust and 584 shares via the Trigg Family Trust.
• Form signed by John L. Brottem for Leslie Trigg on 11/18/2025.

Sentiment

Score: 5

Explanation: Neutral administrative insider transaction with no implications for operations, guidance, or fundamentals.

Positives

• Sale explicitly designated as a sell-to-cover for tax withholding, indicating no discretionary trading intent.
• CEO retains significant stake post-transaction: 121,412 shares directly and 42,250 shares indirectly via family trusts.

Negatives

• Direct ownership decreased by 916 shares due to the sale.

Future Outlook

No forward-looking statements or operational guidance disclosed; the report reflects an administrative sell-to-cover transaction for tax withholding.

Management Comments

• Sale executed solely to satisfy tax withholding obligations related to RSU vesting; it does not represent a discretionary trade.
• RSUs tied to this withholding were granted on 01/06/2023 and 01/12/2024.

Industry Context

Administrative sell-to-cover transactions around equity award vesting are common among U.S.-listed companies and typically do not indicate changes in company strategy or fundamentals.

Comparison to Industry Standards

• Nature and timing of the sell-to-cover align with standard executive compensation practices widely observed across medtech and broader U.S. public companies.
• Post-transaction ownership remains sizable for a CEO, consistent with executive shareholding norms designed to align management and shareholder interests.

Stakeholder Impact

• Minimal impact expected; sale is a routine tax withholding transaction.
• Updated transparency on insider holdings: 121,412 shares directly and 42,250 shares indirectly via family trusts.

Key Dates

Keywords

Outset Medical, OM, Form 4, insider transaction, sell-to-cover, RSU vesting, Leslie Trigg, CEO, beneficial ownership, tax withholding